Syndax Pharmaceuticals Inc expected to post a loss of 65 cents a share - Earnings Preview

Syndax Pharmaceuticals

25/02/2023 03:06

* Syndax Pharmaceuticals Inc  SNDX.OQ   SNDX.O  is expected
to show a fall in quarterly revenue when it reports  results on
February 28. 
    * The Waltham Massachusetts-based  company is expected to
report 
a 99.7% decrease in revenue to $375 thousand from $126.58
million a year ago, according to the mean estimate from 8
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Syndax
Pharmaceuticals
Inc is for a loss of 65 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Syndax
Pharmaceuticals Inc is $33.5​, above​ its last closing price
of $23.98. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.64       -0.63      -0.58     Beat    8.7
 Jun. 30 2022  -0.66       -0.64      -0.62     Beat    2.6
 Mar. 31 2022  -0.63       -0.63      -0.63     Met     0.8​
 Dec. 31 2021  0.23        0.28       1.81      Beat    550.3
 ​​Sep.        0.01        -0.23      -0.40     Missed  -72.7
 30 2021                                                
 Jun. 30 2021  -0.72       -0.71      -0.44     Beat    38.5​
 Mar. 31 2021  -0.65       -0.65      -0.54     Beat    16.7
 Dec. 31 2020  -0.44       -0.49      -0.44     Beat    9.6
 This summary was machine generated February 25 at 03:05 GMT. 
All figures in US dollars  unless otherwise stated